CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen
about
Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.Prognostic impact of membranous ATP-binding cassette Sub-family G member 2 expression in patients with colorectal carcinoma after surgical resection.Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue.Topoisomerase I expression is associated with prognosis in postoperative non-small cell lung cancer patientsClinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors.Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance.Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review.Artemisinin Derivatives Target Topoisomerase 1 and Cause DNA Damage in Silico and in Vitro.Imaging the delivery of drug-loaded, iron-stabilized micelles.Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5-fluorouracil- and oxaliplatin-based preoperative chemotherapy for liver metastases.
P2860
Q36246729-DECC81E2-E8CD-4F99-AAD7-191F7BB1731FQ36838947-EA774657-564E-4DDB-BF5A-A54A4EDC420BQ36964887-0A326192-07AC-4FE3-8EE9-7F4BEC10681CQ37060409-15A2564F-BBA5-418C-A7E2-4CF69B48CD2AQ37544686-0D6EEDF7-3866-423F-97EB-FEF99CB9666DQ38901400-0E147226-B282-40E3-B376-CC64717CD972Q41660826-E89FF4AC-B13E-4D4A-9781-B5DB49A34F50Q43939294-C8095314-8507-4576-849B-C0E0D6C8B213Q54947023-59A99F77-9D88-4885-83CB-D4856A3C417DQ55424081-0B6FE573-539C-4FC5-9EA5-8E373399C0E0
P2860
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
CES2, ABCG2, TS and Topo-I pri ...... ith first-line FOLFIRI regimen
@ast
CES2, ABCG2, TS and Topo-I pri ...... ith first-line FOLFIRI regimen
@en
CES2, ABCG2, TS and Topo-I pri ...... ith first-line FOLFIRI regimen
@nl
type
label
CES2, ABCG2, TS and Topo-I pri ...... ith first-line FOLFIRI regimen
@ast
CES2, ABCG2, TS and Topo-I pri ...... ith first-line FOLFIRI regimen
@en
CES2, ABCG2, TS and Topo-I pri ...... ith first-line FOLFIRI regimen
@nl
prefLabel
CES2, ABCG2, TS and Topo-I pri ...... ith first-line FOLFIRI regimen
@ast
CES2, ABCG2, TS and Topo-I pri ...... ith first-line FOLFIRI regimen
@en
CES2, ABCG2, TS and Topo-I pri ...... ith first-line FOLFIRI regimen
@nl
P2093
P2860
P50
P356
P1476
CES2, ABCG2, TS and Topo-I pri ...... ith first-line FOLFIRI regimen
@en
P2093
Angelo Paradiso
Anna Elisabetta Brunetti
Giovanni Simone
Giulia Partipilo
Nicola Silvestris
Vito Lorusso
P2860
P304
15767-15777
P356
10.3390/IJMS150915767
P407
P577
2014-09-05T00:00:00Z